Connective tissue diseases (CTDs) are a heterogeneous group of systemic diseases associated with a risk of developing several cardiopulmonary comorbidities, including pulmonary arterial hypertension (PAH).1 PAH associated with CTD (PAH-CTD) accounts for ~25% of all PAH cases, with the highest rates in individuals with systemic sclerosis (SSc)—up to ~15% of whom will develop PAH1; guidelines advocate for annual screening.2
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
